Compare Johnson & Johnson (JNJ) vs Nu Holdings Ltd (NU) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

NU stock trades at $14.125, up 3.94% today, with a bearish technical signal but strong fundamentals including 26.72% net income margin and 30.04% ROE. Recent earnings show mixed results with two misses, but revenue growth accelerated from $3.0B in 2022 to $10.63B in 2025. The company secured banking approval in Mexico, expanding its Latin American footprint to 15 million customers as of July 2026 (Bloomberg, 2026-07-15).

Outlook remains positive with a $14.98 consensus price target (54.55% buy ratings), though risks include high P/E of 20.96 and debt-to-asset ratio volatility. Growth catalysts from Mexico expansion and digital banking dominance support long-term potential, but near-term headwinds from earnings misses and competitive pressures warrant caution.